RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
36 hedge funds and large institutions have $27.9M invested in RVL Pharmaceuticals plc Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 11 closing their positions.
9,650% more call options, than puts
Call options by funds: $195K | Put options by funds: $2K
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
22% less funds holding
Funds holding: 46 → 36 (-10)
45% less capital invested
Capital invested by funds: $50.5M → $27.9M (-$22.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.69M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$431K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$169K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$50.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$40.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$580K |
| 2 |
Morgan Stanley
New York
|
-$122K |
| 3 |
Renaissance Technologies
New York
|
-$90.5K |
| 4 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$36.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$34K |
RVLP Hedge Fund Activity: Q4 2022 in Review
36 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2022, worth a combined $27.9M — down 45% from $50.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RVLP and 1 opened new positions — a net loss of 10 holders — while 6 trimmed existing stakes and 13 added.
The largest buyer was AIGH Capital Management, adding an estimated $1.69M. The largest seller was UBS O'Connor, exiting entirely with an estimated $580K sold.
- 36 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2022, down from 46 in Q3 2022.
- Funds reported $27.9M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2022, down 45% quarter-over-quarter.
- 1 fund opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2022 and 11 closed out, a net change of -10 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2022 was AIGH Capital Management, an estimated $1.69M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2022 was UBS O'Connor, an estimated $580K sold.
Based on aggregated 13F filings for Q4 2022.